Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 17, 2021updated 07 Jan 2022 8:47am

Ethos unveils new sample collection kit for Covid-19 antibody test

The new self-collection kit allows individuals to measure their current immunity levels against Covid-19.

Ethos Laboratories has launched the new fingerstick self-blood collection kit, Tru-Immune, for its Covid-19 neutralising antibody test.

The kit provides quantitative data regarding the viral blocking efficacy of neutralising antibodies.

Individuals can use the kit to measure their current immunity levels against Covid-19 safely, rapidly and efficiently in real-time with less pain.

Additionally, it will help people monitor their neutralising antibody level and reduce the chances to get infected.

The Tru-Immune uses a simple drop of capillary blood from the patients’ fingertip, which will be returned to Ethos through prepaid and priority postage. It delivers the results in 48 hours electronically.

Ethos Laboratories CEO Brian Kincaid said: “As we enter year three of the Covid-19 global pandemic, the question is no longer, ‘Do I have Covid-19 antibodies?’ Instead, people are asking themselves, ‘What level of protective immunity do I have against future infection and do I need a vaccine booster?’ These questions can now be answered with Tru-Immune.”

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

The Covid-19 neutralising antibody tests will provide information regarding the immunity levels against the disease in the individual.

This will help the healthcare provider to make decisions regarding vaccination and booster schedules.

Ethos noted that the neutralising antibody assays like Tru-Immune are expected to become the assay of choice to record natural immunity in states, where employers need proof to get exemption from mandates with regard to vaccines.

In April, Ethos introduced a new molecular test to detect key virus strains of SARS-CoV-2, including the UK (B.1.1.7), South Africa (B.1.351) and Brazil (P.1) variants.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy